Concord Biotech Q4 FY25 Earnings Results: Net Profit Jumps 48%, Revenue up 35%

On May 30, 2025, Concord Biotech shares surged over 6% to an intraday high of ₹1,761, following the announcement of robust Q4FY25 results. By 10:10 AM, the stock was trading 4.43% higher at ₹1,740.75, while the BSE Sensex was slightly down by 0.13%.

Concord Biotech: Q4 FY25 Financial Highlights

• Net Profit: ₹140 crore, up 47.8% from ₹95 crore in Q4FY24
• Revenue: ₹429.9 crore, a rise of 34.8% from ₹319 crore a year earlier
• EBITDA: ₹190.4 crore, up 41.8% YoY
• EBITDA Margin: Improved to 44.3% from 42.1%

Dividend Announcement

The board recommended a final dividend of ₹10.70 per equity share for FY25, subject to shareholder approval at the upcoming AGM.

Also Read: Infosys Partners with LogicMonitor to Boost IT Operations Efficiency! 

About Concord Biotech

Founded in 2000, Concord Biotech is a research-driven biopharma company that produces Active Pharmaceutical Ingredients (APIs) using fermentation and semi-synthetic methods. It also manufactures finished formulations and exports to over 70 countries, including the USA, Europe, Japan, and Latin America. The company has three manufacturing facilities near Ahmedabad, Gujarat:

• Dholka Plant (2000): Specialises in APIs; certified by USFDA, EUGMP, PMDA
• Valthera Facility (2016): Makes oral solids and liquids; injectable line expansion planned
• Limbasi Plant (2021): Focuses on advanced fermentation and API processing

Concord Biotech is listed under the BSE 500 and has a market cap of ₹18,682 crore as per the BSE.

Conclusion

Concord Biotech's impressive Q4 results, with solid growth in profit and revenue, improved margins, and a strong dividend payout, have boosted investor confidence. The company’s global presence and continued expansion in manufacturing capabilities make it a strong player in the biopharma sector.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.